Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Area of Science:

• Oncolytic virotherapy
• Cancer immunotherapy
• Molecular virology

Background:

• Cancer immunotherapy shows promise for long-term tumor control but requires personalized approaches.
• Oncolytic viruses offer a dual mechanism for cancer treatment: direct tumor lysis and induction of anti-tumor immunity.
• There is a need for adaptable platforms to generate tailored oncolytic virus agents.

Purpose of the Study:

• To describe a comprehensive protocol for generating and analyzing immunomodulatory oncolytic vectors.
• To provide a adaptable methodology for engineering oncolytic viruses, exemplified by measles virus vectors encoding bispecific T cell engagers.
• To facilitate the development of novel oncolytic agents for preclinical and clinical translation.

Main Methods:

• Design, cloning, rescue, and propagation of recombinant oncolytic viruses.
• Ex vivo analysis of vector replication kinetics and tumor cell lysis.
• Functional assessment of immunomodulators (e.g., bispecific T cell engagers) expressed by the vector.

Main Results:

• Demonstrated a workflow for generating recombinant measles virus vectors encoding immunomodulators.
• Established assays for evaluating oncolytic vector performance and immunomodulator activity.
• Provided a framework for adapting the methodology to various virus backbones and transgenes.

Conclusions:

• The described protocol enables the generation of customized oncolytic virus therapies.
• This adaptable methodology supports the development of next-generation oncolytic agents for cancer treatment.
• The workflow facilitates the progression of oncolytic virus research from laboratory to clinical application.